Oxford-AstraZeneca vaccine was seen 795 effective in preventing symptomatic illness in the US, Peru, and Chile trials.

The drug Maker said on Monday that the vaccine was 100% effective to prevent critical disease and hospitalization. AstraZeneca released results of late-stage human trials volunteered by 32,000 people.

The data paves the way for it to be approved in the United States. The statistics provide the vaccine credibility against the disruption by various European countries, which have said the vaccine is responsible for the blood clot.

Manby countries in Europe briefly halted the use of the AstraZeneca Vaccine which has now mostly been resumed  after a regional regulator said it was safe

AstraZeneca clarified the allegations by saying “no increased risk of thrombosis or events characterized by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial”.